About us
In brief
The Board of Directors
Management Team
Corporate Governance
Intellectual Properties
Partnerships
Environment & quality
Human Resources
Career
Project portfolio
Project overview
Research areas
Development phases
Publications
Contract Research
Autoradiography
Pharmacokinetics & Metabolism
Analytical chemistry
Disease models
Investor info
Contacts
Press releases
Stock
Interim reports
Annual reports
Presentations
Ownership
Official documents
Calender
Press & news
Press releases
Interim reports
Annual reports
Features
Image bank
Calender
Contacts
Reports
Contact
Contacts
Visit us
FAQ
Treating MS:
Laquinimod – a promising project
Feature: ANYARA – the targeted cancer therapy
Benefit from our edge competence in drug development
Active Biotech develops innovative pharmaceuticals that modulate the body's own immune system.We focus on widespread diseases for which a tremendous need is felt for new and more effective treatments.
2010-08-11
Active Biotech AB Interim report January - June 2010
2010-07-30
Number of shares and votes in Active Biotech
2010-06-30
Number of shares and votes in Active Biotech
2010-06-10
Active Biotech Capital Markets Day
2010-06-07
Active Biotech's TASQ prostate cancer project presented at ASCO
2010-05-21
Active Biotech's TASQ prostate cancer project to be presented at ASCO
Advanced search
Active Biotech Capital Markets Day
June 10, 2010 at 2 pm CEST
Listen to the presentation >>
Download the presentation >>
Annual General Meeting - May 6, 2010
Read more >>
”Molecular and Cellular Biology of Immune Escape in Cancer” Keystone symposia, Colorado, USA, February 7-12, 2010
View the ANYARA poster here>>
Annual Report 2009
Read the report here >>
Subscribe to press releases from Active Biotech
Fill in form >>
Active Biotech AB, Scheelevägen 22, P.O. Box 724, SE-220 07 Lund, Sweden, Telephone +46 46 19 20 00